SCYNEXIS INC (SCYX) Stock Price, Quote, News and Overview
NASDAQ:SCYX - Nasdaq - US8112922005 - Common Stock - Currency: USD
SCYX Quote, Performance and Key Statistics
NASDAQ:SCYX (5/6/2025, 3:57:05 PM)
0.95
-0.02 (-2.06%)
The current stock price of SCYX is 0.95 USD. In the past month the price increased by 15.37%. In the past year, price decreased by -50.05%.
SCYX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.35 | 735.06B | ||
| JNJ | JOHNSON & JOHNSON | 15.37 | 371.57B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.2 | 294.11B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 218.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.88 | 217.75B | ||
| MRK | MERCK & CO. INC. | 10.14 | 198.79B | ||
| SNY | SANOFI-ADR | 13.8 | 130.10B | ||
| PFE | PFIZER INC | 7.13 | 129.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.47 | 96.65B | ||
| GSK | GSK PLC-SPON ADR | 6.86 | 75.88B | ||
| ZTS | ZOETIS INC | 25.25 | 66.68B | ||
| HLN | HALEON PLC-ADR | 21.76 | 48.07B |
Related stock screener links
About SCYX
Company Profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 28 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Company Info
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City NEW JERSEY 07302 US
CEO: Marco Taglietti
Employees: 28
Phone: 12018845485
SCYNEXIS INC / SCYX FAQ
What is the stock price of SCYNEXIS INC today?
The current stock price of SCYX is 0.95 USD. The price decreased by -2.06% in the last trading session.
What is the ticker symbol for SCYNEXIS INC stock?
The exchange symbol of SCYNEXIS INC is SCYX and it is listed on the Nasdaq exchange.
On which exchange is SCYX stock listed?
SCYX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCYNEXIS INC stock?
9 analysts have analysed SCYX and the average price target is 5.1 USD. This implies a price increase of 436.84% is expected in the next year compared to the current price of 0.95. Check the SCYNEXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCYNEXIS INC worth?
SCYNEXIS INC (SCYX) has a market capitalization of 37.03M USD. This makes SCYX a Nano Cap stock.
How many employees does SCYNEXIS INC have?
SCYNEXIS INC (SCYX) currently has 28 employees.
What are the support and resistance levels for SCYNEXIS INC (SCYX) stock?
SCYNEXIS INC (SCYX) has a support level at 0.96 and a resistance level at 1.03. Check the full technical report for a detailed analysis of SCYX support and resistance levels.
Is SCYNEXIS INC (SCYX) expected to grow?
The Revenue of SCYNEXIS INC (SCYX) is expected to grow by 58.74% in the next year. Check the estimates tab for more information on the SCYX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SCYNEXIS INC (SCYX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCYX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCYX, evaluating the profitability, health, valuation and growth aspects
- SCYNEXIS INC (SCYX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCYNEXIS INC (SCYX) Sales and EPS estimates to see what analysts future expectations are.
- SCYNEXIS INC (SCYX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCYNEXIS INC (SCYX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCYNEXIS INC (SCYX) Stock Chart to make your own analysis
- SCYNEXIS INC (SCYX) Latest news and press-releases to stay up to date.
Does SCYNEXIS INC (SCYX) stock pay dividends?
SCYX does not pay a dividend.
When does SCYNEXIS INC (SCYX) report earnings?
SCYNEXIS INC (SCYX) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of SCYNEXIS INC (SCYX)?
SCYNEXIS INC (SCYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
What is the Short Interest ratio of SCYNEXIS INC (SCYX) stock?
The outstanding short interest for SCYNEXIS INC (SCYX) is 1.82% of its float. Check the ownership tab for more information on the SCYX short interest.
SCYX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCYX. When comparing the yearly performance of all stocks, SCYX is a bad performer in the overall market: 87.92% of all stocks are doing better.
SCYX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SCYX. SCYX may be in some trouble as it scores bad on both profitability and health.
SCYX Financial Highlights
Over the last trailing twelve months SCYX reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS decreased by -133.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.49% | ||
| ROE | -38.65% | ||
| Debt/Equity | 0.25 |
SCYX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to SCYX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 26.98% and a revenue growth 58.74% for SCYX